Monthly Archives: December 2017

http://www.lslog.com/valeant-pershing-square-settle-insider-trading-cases-for-290m/Valeant, Pershing Square settle insider trading cases for $290M

Valeant, Pershing Square settle insider trading cases for $290M

Valeant, Pershing Square settle insider trading cases for 0M After playing defense against insider trading allegations for several years, Valeant and Pershing Square are settling with Allergan investors for $290 […]

http://www.lslog.com/judge-overturns-150m-androgel-verdict-against-abbvie/Judge overturns $150M AndroGel verdict against AbbVie

Judge overturns $150M AndroGel verdict against AbbVie

Judge overturns 0M AndroGel verdict against AbbVie Ever since AbbVie took its first major loss in its AndroGel liability litigation—a $150 million verdict back in July—the drugmaker has insisted that […]

http://www.lslog.com/could-a-three-part-diabetes-drug-ease-memory-loss-in-alzheimers/Could a three-part diabetes drug ease memory loss in Alzheimer’s?

Could a three-part diabetes drug ease memory loss in Alzheimer’s?

Could a three-part diabetes drug ease memory loss in Alzheimer’s? The Alzheimer’s field is littered with drug-development failures, but that isn’t deterring a group of British scientists from looking for […]

http://www.lslog.com/bioengineers-mimic-natural-development-to-create-complex-living-tissues/Bioengineers mimic natural development to create complex living tissues

Bioengineers mimic natural development to create complex living tissues

Bioengineers mimic natural development to create complex living tissues The field of tissue engineering has advanced to the point where bioengineers can use 3D printing to grow human tissues like […]

http://www.lslog.com/using-an-old-merck-drug-menlo-hopes-to-scratch-an-itch-with-98m-ipo/Using an old Merck drug, Menlo hopes to scratch an itch with $98M IPO

Using an old Merck drug, Menlo hopes to scratch an itch with $98M IPO

Using an old Merck drug, Menlo hopes to scratch an itch with M IPO Six months after getting off a $50 million series C, late-stage California dermatology biotech Menlo Therapeutics […]

http://www.lslog.com/fresenius-oncology-drug-plant-slammed-with-new-warning-letter/Fresenius oncology drug plant slammed with new warning letter

Fresenius oncology drug plant slammed with new warning letter

Fresenius oncology drug plant slammed with new warning letter A Fresenius Kabi cancer drug plant in India savaged by the FDA in the past for hiding serious drug testing issues, […]

http://www.lslog.com/a-car-t-approach-to-attacking-hiv/A CAR-T approach to attacking HIV

A CAR-T approach to attacking HIV

A CAR-T approach to attacking HIV Engineered immune cells known as chimeric antigen receptor T cells (CAR-T) have grabbed headlines this year for their potential to cure some patients with […]

http://www.lslog.com/mallinckrodt-inks-1-2b-sucampo-buy-ending-rough-2017-on-a-high-note/Mallinckrodt inks $1.2B Sucampo buy, ending rough 2017 on a high note

Mallinckrodt inks $1.2B Sucampo buy, ending rough 2017 on a high note

Mallinckrodt inks .2B Sucampo buy, ending rough 2017 on a high note Mallinckrodt, which has landed in hot water multiple times this year, is diversifying beyond its controversial lead seller. […]

http://www.lslog.com/roche-snags-another-perjeta-combo-nod-but-will-weak-data-limit-its-use/Roche snags another Perjeta combo nod, but will 'weak' data limit its use?

Roche snags another Perjeta combo nod, but will 'weak' data limit its use?

Roche snags another Perjeta combo nod, but will ‘weak’ data limit its use? Roche landed an end-of-the-year indication for Perjeta, but it’s an indication analysts and investors think may not […]

http://www.lslog.com/using-crispr-to-prevent-hearing-loss/Using CRISPR to prevent hearing loss

Using CRISPR to prevent hearing loss

Using CRISPR to prevent hearing loss The emerging gene-editing technique CRISPR-Cas9 is being examined for its potential to prevent hearing loss in people who inherit faulty deafness-causing genes. Scientists at […]